Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development

Bibliography

• Johnson AD, Wang D, Sadee W. Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics. Pharmacol Ther 2005;106(1):19-38
   PubMedGoogle Scholar
• Kimchi-Sarfaty C, Oh JM, Kim IW, A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315(5811):525-8
   PubMed Web of Science ®Google Scholar
• Scott SA, Edelmann L, Kornreich R, CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. Pharmacogenomics 2007;8(7):721-30
   PubMed Web of Science ®Google Scholar
• Brockmoller J, Tzvetkov MV. Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol 2008;64(2):133-57
   PubMed Web of Science ®Google Scholar
• Hapmap. Available from: http://hapmap.ncbi.nlm.nih.gov/
   Google Scholar
• UCSF-Pharmacogenetics. Available from: http://pharmacogenetics.ucsf.edu/
   Google Scholar
• EVS. Available from: http://evs.gs.washington.edu/EVS
   Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, Membrane transporters in drug development. Nat Rev Drug Discov 2010;9(3):215-36
   PubMed Web of Science ®Google Scholar
• Kusuhara H, Sugiyama Y. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 2009;24(1):37-52
   PubMed Web of Science ®Google Scholar
• Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005;26(4):178-82
   PubMed Web of Science ®Google Scholar
• Gregori-Puigjane E, Mestres J. A ligand-based approach to mining the chemogenomic space of drugs. Comb Chem High Throughput Screen 2008;11(8):669-76
   PubMed Web of Science ®Google Scholar
• Hughes JD, Blagg J, Price DA, Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008;18(17):4872-5
   PubMed Web of Science ®Google Scholar
• Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44(1):235-49
   PubMed Web of Science ®Google Scholar
• Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J 2011;13(4):519-47
   PubMed Web of Science ®Google Scholar
• Varma MV, Ambler CM, Ullah M, Targeting intestinal transporters for optimizing oral drug absorption. Curr Drug Metab 2010;11(9):730-42
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling L. A surface glycoprotein on modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;555:152-62
   Google Scholar
• Lee CA, Cook JA, Reyner EL, P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol 2010;6(5):603-19
   PubMed Web of Science ®Google Scholar
• Thiebut F, Tsuruo T, Hamada H, Cellular localisation of the multidrug resistance gene product P-glycoprotien in normal human tissues. Proc National Acad Sci USA 1987;84:7735-8
   PubMedGoogle Scholar
• Mahar Doan KM, Humphreys JE, Webster LO, Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 2002;303(3):1029-37
   PubMed Web of Science ®Google Scholar
• Polli JW, Wring SA, Humphreys JE, Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001;299(2):620-8
   PubMed Web of Science ®Google Scholar
• Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 2006;109(1-2):137-61
   PubMed Web of Science ®Google Scholar
• Varma MVS, Ashokraj Y, Dey CS, P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003;48:347-59
   PubMed Web of Science ®Google Scholar
• Sasongko L, Link JM, Muzi M, Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 2005;77(6):503-14
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, von Richter O, Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97(7):3473-8
   PubMed Web of Science ®Google Scholar
• Wang D, Sadee W. Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). AAPS J 2006;8(3):E515-20
   Google Scholar
• Kurata Y, Ieiri I, Kimura M, Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002;72(2):209-19
   PubMed Web of Science ®Google Scholar
• Cho HY, Yoo HD, Lee YB. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects. Neuroscience 2010;169(1):378-87
   PubMedGoogle Scholar
• Fiegenbaum M, da Silveira FR, Van der Sand CR, The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005;78(5):551-8
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008;84(4):457-61
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Nakamura T, Horinouchi M, MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001;18(10):1400-4
   PubMed Web of Science ®Google Scholar
• Gerloff T, Schaefer M, Johne A, MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002;54(6):610-16
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Kurkinen KJ, Neuvonen M, No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol 2009;68(2):207-13
   PubMed Web of Science ®Google Scholar
• Chowbay B, Li H, David M, Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 2005;60(2):159-71
   PubMed Web of Science ®Google Scholar
• Jiang ZP, Wang YR, Xu P, Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics. Basic Clin Pharmacol Toxicol 2008;103(5):433-44
   PubMed Web of Science ®Google Scholar
• Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006;112(2):457-73
   PubMed Web of Science ®Google Scholar
• Stieger B, Meier PJ. Pharmacogenetics of drug transporters in the enterohepatic circulation. Pharmacogenomics 2011;12(5):611-31
   PubMed Web of Science ®Google Scholar
• Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22(47):7340-58
   PubMed Web of Science ®Google Scholar
• Huang L, Wang Y, Grimm S. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 2006;34(5):738-42
   PubMed Web of Science ®Google Scholar
• Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 2009;5(7):703-29
   PubMed Web of Science ®Google Scholar
• Merino G, Jonker JW, Wagenaar E, Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab Dispos 2005;33(5):614-18
   PubMedGoogle Scholar
• Ando T, Kusuhara H, Merino G, Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos 2007;35(10):1873-9
   PubMed Web of Science ®Google Scholar
• Imai Y, Nakane M, Kage K, C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002;1(8):611-16
   PubMed Web of Science ®Google Scholar
• Morisaki K, Robey RW, Ozvegy-Laczka C, Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 2005;56(2):161-72
   PubMed Web of Science ®Google Scholar
• Cusatis G, Gregorc V, Li J, Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 2006;98(23):1739-42
   PubMedGoogle Scholar
• Urquhart BL, Ware JA, Tirona RG, Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics 2008;18(5):439-48
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Ieiri I, Kusuhara H, Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther 2008;84(1):95-103
   PubMed Web of Science ®Google Scholar
• Adkison KK, Vaidya SS, Lee DY, Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. J Pharm Sci 2010;99(2):1046-62
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Zolk O, Fromm MF, ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009;86(2):197-203
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Pasanen MK, Neuvonen PJ, Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 2009;10(10):1617-24
   PubMed Web of Science ®Google Scholar
• Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 2003;33(Suppl 2):1-5
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63(1):157-81
   PubMed Web of Science ®Google Scholar
• Niemi M, Schaeffeler E, Lang T, High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004;14(7):429-40
   PubMedGoogle Scholar
• Lau YY, Huang Y, Frassetto L, Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 2007;81(2):194-204
   PubMed Web of Science ®Google Scholar
• Poirier A, Funk C, Lave T, New strategies to address drug-drug interactions involving OATPs. Curr Opin Drug Discov Devel 2007;10(1):74-83
   PubMedGoogle Scholar
• Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005;1(3):429-45
   PubMedGoogle Scholar
• Regazzi MB, Iacona I, Campana C, Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993;25(4):2732-4
   PubMed Web of Science ®Google Scholar
• Schneck DW, Birmingham BK, Zalikowski JA, The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004;75(5):455-63
   PubMed Web of Science ®Google Scholar
• Tirona RG, Leake BF, Merino G, Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001;276(38):35669-75
   PubMed Web of Science ®Google Scholar
• Mwinyi J, Johne A, Bauer S, Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004;75(5):415-21
   PubMed Web of Science ®Google Scholar
• Nishizato Y, Ieiri I, Suzuki H, Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003;73(6):554-65
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008;9(1):19-33
   PubMed Web of Science ®Google Scholar
• Seithel A, Glaeser H, Fromm MF, The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert Opin Drug Metab Toxicol 2008;4(1):51-64
   PubMed Web of Science ®Google Scholar
• Marciante KD, Durda JP, Heckbert SR, Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 2011;21(5):280-8
   PubMed Web of Science ®Google Scholar
• Iwai M, Suzuki H, Ieiri I, Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 2004;14(11):749-57
   PubMedGoogle Scholar
• Kalliokoski A, Neuvonen M, Neuvonen PJ, The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br J Clin Pharmacol 2008;66(6):818-25
   PubMed Web of Science ®Google Scholar
• Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 2007;24(2):239-47
   PubMed Web of Science ®Google Scholar
• Katz DA, Carr R, Grimm DR, Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther 2006;79(3):186-96
   PubMed Web of Science ®Google Scholar
• Maeda K, Ieiri I, Yasuda K, Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 2006;79(5):427-39
   PubMed Web of Science ®Google Scholar
• Lee E, Ryan S, Birmingham B, Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78(4):330-41
   PubMed Web of Science ®Google Scholar
• Choi JH, Lee MG, Cho JY, Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Ther 2008;83(2):251-7
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16(12):873-9
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J, SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med 2008;359(8):789-99
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006;80(4):356-66
   PubMed Web of Science ®Google Scholar
• Tachibana-Iimori R, Tabara Y, Kusuhara H, Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 2004;19(5):375-80
   PubMedGoogle Scholar
• Igel M, Arnold KA, Niemi M, Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 2006;79(5):419-26
   PubMed Web of Science ®Google Scholar
• Rodrigues AC, Perin PM, Purim SG, Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci 2011;12(9):5815-27
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Kajosaari LI, Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005;77(6):468-78
   PubMed Web of Science ®Google Scholar
• Letschert K, Keppler D, Konig J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004;14(7):441-52
   PubMedGoogle Scholar
• Picard N, Yee SW, Woillard JB, The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther 2010;87(1):100-8
   PubMed Web of Science ®Google Scholar
• Smith NF, Marsh S, Scott-Horton TJ, Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007;81(1):76-82
   PubMed Web of Science ®Google Scholar
• Dresser MJ, Leabman MK, Giacomini KM. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci 2001;90(4):397-421
   PubMed Web of Science ®Google Scholar
• Somogyi A, Bochner F. Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. Br J Clin Pharmacol 1984;18(2):175-81
   PubMed Web of Science ®Google Scholar
• Kimura N, Okuda M, Inui K-I. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res 2005;22(2):255-9
   PubMed Web of Science ®Google Scholar
• Leabman MK, Huang CC, Kawamoto M, Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenomics 2002;12(5):395-405
   Google Scholar
• Song IS, Shin HJ, Shim EJ, Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 2008;84(5):559-62
   PubMed Web of Science ®Google Scholar
• Chen Y, Li S, Brown C, Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 2009;19(7):497-504
   PubMed Web of Science ®Google Scholar
• Zolk O, Solbach TF, Konig J, Functional characterization of the human organic cation transporter 2 variant p.270Ala > Ser. Drug Metab Dispos 2009;37(6):1312-18
   PubMed Web of Science ®Google Scholar
• Wang ZJ, Yin OQ, Tomlinson B, OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 2008;18(7):637-45
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Vormfelde SV, Balen D, The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009;86(3):299-306
   PubMed Web of Science ®Google Scholar
• Christensen MM, Brasch-Andersen C, Green H, The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011;21(12):837-50
   PubMed Web of Science ®Google Scholar
• Filipski KK, Mathijssen RH, Mikkelsen TS, Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 2009;86(4):396-402
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Behrens G, O'Brien VP, Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics 2011;12(10):1417-27
   PubMed Web of Science ®Google Scholar
• Fujita T, Brown C, Carlson EJ, Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet Genomics 2005;15(4):201-9
   PubMedGoogle Scholar
• Bleasby K, Hall LA, Perry JL, Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6). J Pharmacol Exp Ther 2005;314(2):923-31
   PubMed Web of Science ®Google Scholar
• Erdman AR, Mangravite LM, Urban TJ, The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am J Physiol Renal Physiol 2006;290(4):F905-12
   PubMed Web of Science ®Google Scholar
• Wang DS, Jonker JW, Kato Y, Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002;302(2):510-15
   PubMed Web of Science ®Google Scholar
• van Montfoort JE, Muller M, Groothuis GM, Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther 2001;298(1):110-15
   PubMed Web of Science ®Google Scholar
• Takane H, Shikata E, Otsubo K, Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008;9(4):415-22
   PubMed Web of Science ®Google Scholar
• Shu Y, Leabman MK, Feng B, Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 2003;100(10):5902-7
   PubMed Web of Science ®Google Scholar
• Shu Y, Sheardown SA, Brown C, Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117(5):1422-31
   PubMed Web of Science ®Google Scholar
• Shu Y, Brown C, Castro RA, Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008;83(2):273-80
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Saadatmand AR, Bokelmann K, Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J 2012;12(1):22-9
   PubMed Web of Science ®Google Scholar
• Otsuka M, Matsumoto T, Morimoto R, A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 2005;102(50):17923-8
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, van Schaik RHN, Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009;58(3):745-9
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, van Schaik RH, Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics 2010;20(1):38-44
   PubMed Web of Science ®Google Scholar
• Toyama K, Yonezawa A, Tsuda M, Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenet Genomics 2010;20(2):135-8
   PubMed Web of Science ®Google Scholar
• Choi JH, Yee SW, Ramirez AH, A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther 2011;90(5):674-84
   PubMed Web of Science ®Google Scholar
• Carlton VE, Pawlikowska L, Bull LN. Molecular basis of intrahepatic cholestasis. Ann Med 2004;36(8):606-17
   PubMed Web of Science ®Google Scholar
• Lang T, Haberl M, Jung D, Genetic variability, haplotype structures, and ethnic diversity of hepatic transporters MDR3 (ABCB4) and bile salt export pump (ABCB11). Drug Metab Dispos 2006;34(9):1582-99
   PubMed Web of Science ®Google Scholar
• Lang C, Meier Y, Stieger B, Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007;17(1):47-60
   PubMed Web of Science ®Google Scholar
• Ho RH, Leake BF, Kilkenny DM, Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenet Genomics 2010;20(1):45-57
   PubMed Web of Science ®Google Scholar
• Niemi M, Arnold KA, Backman JT, Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics 2006;16(11):801-8
   PubMed Web of Science ®Google Scholar
• Kivisto K, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 2007;24(2):239-47
   PubMed Web of Science ®Google Scholar
• Deo AK, Prasad B, Balogh L, Inter-individual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by LC/MS/MS. Drug Metab Dispos 2012; Epub Date: Feb 13, 2012 Doi 10.1124/dmd.111.043810
   PubMedGoogle Scholar
• Ho RH, Choi L, Lee W, Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics 2007;17(8):647-56
   PubMed Web of Science ®Google Scholar
• Fujita T, Urban TJ, Leabman MK, Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 2006;95(1):25-36
   PubMed Web of Science ®Google Scholar
• Fukushima-Uesaka H, Maekawa K, Ozawa S, Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab Pharmacokinet 2004;19(3):239-44
   PubMedGoogle Scholar
• Kang H-J, Song I-S, Shin HJ, Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab Dispos 2007;35(4):667-75
   PubMedGoogle Scholar
• Sakata T, Anzai N, Shin HJ, Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun 2004;313(3):789-93
   PubMed Web of Science ®Google Scholar
• Kerb R, Brinkmann U, Chatskaia N, Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 2002;12(8):591-5
   PubMedGoogle Scholar
• Choi MK, Song IS. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet 2008;23(4):243-53
   PubMed Web of Science ®Google Scholar
• Chen L, Takizawa M, Chen E, Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther 2010;335(1):42-50
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Ieiri I, Hirota T, Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 2005;33(1):94-101
   PubMed Web of Science ®Google Scholar
• Kim KT, Birmingham CT, Azumaya CT, Increased systemic exposure to rosuvastatin in Asian subjects residing in the United States compared to Caucasian subjects. Clin Pharmacol Ther 2008;83(Suppl 1):S14
   Google Scholar
• Li N, Singh P, Mandrell KM, Improved extrapolation of hepatobiliary clearance from in vitro sandwich cultured rat hepatocytes through absolute quantification of hepatobiliary transporters. Mol Pharm 2010;7(3):630-41
   PubMedGoogle Scholar
• McClellan J, King MC. Response: why it is time to sequence. Cell 2010;142(3):353-5
   Google Scholar
• Pfefferkorn JA, Litchfield J, Hutchings R, Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution. Bioorg Med Chem Lett 2011;21(9):2725-31
   PubMedGoogle Scholar
• Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004;44(10):1083-105
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Maeda K, Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 2009;328(2):652-62
   PubMed Web of Science ®Google Scholar
• Wadelius M, Chen LY, Downes K, Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005;5(4):262-70
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Gelderblom H, Marsh S, Diflomotecan pharmacokinetics in relation to ABCG2 421C > A genotype. Clin Pharmacol Ther 2004;76(1):38-44
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Loos WJ, Burger H, Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther 2005;4(6):650-8
   PubMed Web of Science ®Google Scholar